R2810-ONC-16XX: A Phase 1 Neoadjuvant Study of Stereotactic Body Radiation Therapy With Systemic REGN2810 and Intraprostatic Ipilimumab, Alone or in Combination, in Patients With Locally Advanced Prostate Cancer Prior to Radical Prostatectomy
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Cemiplimab (Primary) ; Ipilimumab (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 07 Nov 2019 Planned End Date changed from 1 Apr 2020 to 4 Nov 2019.
- 07 Nov 2019 Planned primary completion date changed from 31 Dec 2019 to 4 Nov 2019.
- 07 Nov 2019 Planned initiation date changed from 1 Dec 2018 to 24 Dec 2018.